New combo therapy aims to tame rare bleeding disorder

NCT ID NCT07421167

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 15, 2026 · Updated 6 times

Summary

This study tests a new biologic drug called ianalumab combined with a standard platelet-boosting drug (TPO-RA) in people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The trial includes 164 adults who have tried at least one prior treatment. The main goal is to see how well patients tolerate the combination over 16 weeks, with a focus on side effects and treatment interruptions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ianalumab (a biologic drug) combined with a thrombopoietin receptor agonist (TPO-RA, a drug that boosts platelet production)
What this could lead to: If successful, this combination could offer a new treatment option for people with immune thrombocytopenia (ITP) whose disease is not well controlled with current therapies.
What could go wrong: This is an early-phase (Phase 2) study with a moderate number of participants (164). It primarily measures tolerability, not long-term effectiveness. Side effects from the combination are possible, and results may not apply to all ITP patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY EVANS SYNDROME (ES) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura Evans syndrome primary thrombocytopenia Purpura, Thrombocytopenic, Idiopathic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY EVANS SYNDROME (ES) PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)

Contacts and locations

Locations

Baptist MD Anderson Cancer Center
RECRUITING

Jacksonville, Florida, 32207, United States
DH Cancer Research Center LLC
RECRUITING

Margate, Florida, 33063, United States
Hope And Healing Care
RECRUITING

Hinsdale, Illinois, 60521, United States
Stamford Hospital
RECRUITING

Stamford, Connecticut, 06902, United States
Summit Medical Group
RECRUITING

Summit, New Jersey, 07901, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.